Biology | Free Full-Text | Influence of Performance Status on the Effectiveness of Pembrolizumab Monotherapy in First-Line for Advanced Non-Small-Cell Lung Cancer: Results in a Real-World Population
Kaplan-Meier survival analysis
VYXEOS® Efficacy - Phase 3 Trial Data vs 7+3 | VYXEOS® (daunorubicin and cytarabine)
Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis | Leukemia
Efficacy Results | ONIVYDE® (irinotecan liposome injection) | HCP | Onivyde
Kaplan-Meier curves for overall survival. The median overall survival... | Download Scientific Diagram
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma | NEJM
Metastasectomy and Targeted Therapy for Patients With Spinal Metastases of Renal Cell Carcinoma | International Journal of Spine Surgery
GraphPad Prism 10 Statistics Guide - Determining the median followup time
Efficacy Data | ENHERTU® (fam-trastuzumab deruxtecan-nxki)
Survival curves. (A) Overall survival (median 18.2 months). (B) PS of... | Download Scientific Diagram
NEJM on X: "Nivolumab increases median overall survival by 5.4 months in adv renal cell cancer. #ECC2015 http://t.co/9DSZcnbnAs http://t.co/22qcFuEfzN" / X
estimation - Estimating median survival times from Kaplan-Meier plot inspection - Cross Validated
Median Survival Time - an overview | ScienceDirect Topics
Long-term Survival with Ipilimumab: Experience from a National Expanded Access Program for Patients with Melanoma | Anticancer Research
Survival Analysis in R
Median overall survival according to changes in CA 19-9 | Open-i
PADCEV® (enfortumab vedotin-ejfv) Efficacy in Patients with la/mUC
Survival (time to event) data: median survival times | The BMJ
Cancers | Free Full-Text | Identification of Predictive Factors for Overall Survival and Response during Hypomethylating Treatment in Very Elderly (≥75 Years) Acute Myeloid Leukemia Patients: A Multicenter Real-Life Experience
Efficacy of TAGRISSO® (osimertinib) in Metastatic EGFRm NSCLC
Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study | British Journal of Cancer
Ambiguities in computing the median survival time. - FAQ 44 - GraphPad
MARGENZA® Clinical Results
Prognostic Factors for Gastric Cancer Patients With One Stage IV Factor who Underwent Conversion Surgery | Anticancer Research
